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Abstract: Photodynamic therapy (PDT) is a clinical treatment that combines the effects of visible light irradiation with 
subsequent biochemical events that arise from the presence of a photosensitising drug (possessing no dark toxicity) to cause 
destruction of selected cells. Today, the most common agent used in dermatological PDT is 5-aminolevulinic acid (ALA). 
As a result of its hydrophilic character, ALA penetrates skin lesions poorly when applied topically. Its systemic bioavailability 
is limited and it is known to cause signiﬁ  cant side effects when given orally or intravenously. Numerous chemical derivatives 
of ALA have been synthesised with the aims of either improving topical penetration or enhancing systemic bioavailability, 
while reducing side effects. In vitro cell culture experiments with ALA derivatives have yielded promising results. However, 
if ALA derivatives are to demonstrate meaningful clinical beneﬁ  ts, a rational approach to topical formulation design is 
required, along with a systematic study aimed at uncovering the true potential of ALA derivatives in photodynamic therapy. 
With respect to systemic ALA delivery, more study is required in the developing area of ALA-containing dendrons and 
dendrimers.
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Introduction
Photodynamic therapy (PDT) is a clinical treatment that combines the effects of visible light irradiation 
with subsequent biochemical events that arise from the presence of a photosensitising drug (possessing 
no dark toxicity) to cause destruction of selected cells.1 The photosensitiser, when introduced into the 
body, accumulates in rapidly dividing cells and a measured light dose of appropriate wavelength is then 
used to irradiate the target tissue.
2,3 This activates the drug through a series of electronic excitations 
and elicits a series of cytotoxic reactions, which can be dependent on or, less commonly, independent 
of, the generation of reactive oxygen species.
4
PDT has progressed considerably from the early application of sunlight and haematoporphyrin 
derivative, to the use of Photofrin
®, and to second generation preformed photosensitisers and topical 
(surface) application of the prodrug, 5-aminolevulinic acid (ALA) which leads to in situ synthesis of 
the potent endogenous photosensitiser protoporphyrin IX
5 (Daniell and Hill, 1991). PDT is now used 
for a variety of malignant and pre-malignant skin disorders, as well as certain internal cancers. Topical 
PDT has been reviewed comprehensively.
6–8 The popularity of ALA, as the most commonly studied 
agent for PDT, is clearly evident in the number of published articles on the topic, which has increased 
markedly from 2 in 1991 to about 4000 in 2007.
ALA can be applied topically to lesions to be treated or can be injected directly into them. Alternatively, 
the prodrug can be administered orally or parenterally. While each of these approaches leads to PpIX 
accumulation in the target cells, each is associated with signiﬁ  cant difﬁ  culties. ALA penetration into deep 
lesions is unsatisfactory when applied topically and intralesional injection causes appreciable pain. 
Systemically-administered ALA causes systemic side effects and can only be given in limited doses.50
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Chemical modiﬁ  cation of the parent ALA mol-
ecule is aimed at improving the efﬁ  ciency of ALA-
based PDT by increasing ALA delivery, enhancing 
PpIX accumulation and reducing side effects. This 
review examines the various chemical approaches 
taken to achieve these goals.
Photodynamic Therapy
Mechanism of action of photodynamic 
therapy
The detailed mechanism of action of PDT has been 
discussed extensively elsewhere.
9–11 Briefly, it 
results from the interaction of photons of visible 
light, of appropriate wavelength, with intracellular 
concentrations of photosensitising molecules. Pho-
tosensitisers have a stable electronic conﬁ  guration, 
which is in a singlet state in their lowest or ground 
energy level, °PS
10 (Fig. 1). This means that there 
are no unpaired electron spins.
12,13 Following 
absorption of a photon of light of speciﬁ  c wave-
length, a molecule is promoted to an excited state, 
°PS*, which is also a singlet state and is short-lived 
with a half life between 10
–6 and 10
−9 seconds.
10,11 
The photosensitiser can return to the ground state 
by emitting a photon as light energy, or, in other 
words, by ﬂ  uorescence, or by internal conversion 
with energy lost as heat. Alternatively, the molecule 
may convert to the triplet state, 
2PS
*. This conver-
sion occurs via intersystem crossing, which involves 
a change in the spin of an electron.
14 The triplet 
state photosensitiser has lower energy than the 
singlet state but has a longer lifetime.
The singlet state sensitiser can interact with 
surrounding molecules via Type I reactions, while 
the triplet state sensitiser can interact with its sur-
roundings via Type II reactions. The former type 
of reaction leads to the production of free radicals 
or radical ions, via hydrogen or electron transfer. 
These reactive species, after interaction with 
oxygen, can produce highly reactive oxygen 
species, such as the superoxide and peroxide ani-
ons, which then attack cellular targets.
9 However, 
Type I reactions do not necessarily require oxygen 
and can cause cellular damage directly, through 
the action of free radicals, which may include 
sensitiser radicals. Type II reactions, by contrast, 
require an energy transfer mechanism from the 
triplet-state sensitiser to molecular oxygen, which 
itself normally occupies the triplet ground state, 
2O2
3. Although possessing a short lifetime of 
approximately 10
−6 seconds, a sufﬁ  cient concentra-
tion of highly cytotoxic singlet oxygen, °O2, is 
produced to induce irreversible cell damage.9,11 In 
addition, the photosensitiser is not necessarily 
destroyed, but can return to its ground state by 
phosphorescence without chemical alteration and 
may be able to repeat the process of energy trans-
fer many times.
14 Alternatively, the sensitiser may 
return to ground by transferring its energy to 
molecular oxygen, and may even be destroyed by 
photobleaching due to oxidation.
15 Evidently, many 
effects of PDT are oxygen-dependent and rely on 
the oxygen tension within the target tissue. Type I 
and Type II reactions can occur simultaneously and 
the ratio between the two depend on the photosen-
sitiser, substrate, oxygen concentration and sensi-
tiser to substrate binding.
9 Singlet oxygen 
Figure 1. The mechanism of action of photodynamic therapy. Numbers in superscripts denote the number of unpaired electron spins in each 
molecule. Adapted from Konan et al. (2002).
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is, however, widely believed to be the major dam-
aging species in PDT.
1,2,10 Due to its extreme 
reactivity, singlet oxygen has a short lifespan in a 
cellular environment and limited diffusivity in tis-
sue, allowing it to travel only approximately 0.1 
µm.
16 This, combined with the facts that normal 
tissue may not contain photosensitiser or may not 
be perfused by blood vessels damaged by PDT, 
means that damage to normal cells is minimal.
17
Photosensitisers
The ideal photosensitiser is one that shows a high 
tumour to normal tissue ratio, exhibits rapid accu-
mulation in tumour tissue and is cleared efﬁ  ciently 
from the body.
18,19 Localisation of preformed pho-
tosensitisers in neoplastic tissue has been shown, 
though its mechanism is not completely understood. 
Preformed, lipophilic sensitisers, such as the por-
phyrins and phthalocyanines, when administered 
intravenously, are believed to be transported in the 
bloodstream bound to lipoproteins, such as low 
density lipoproteins (LDLs).
14,20 Tumour cell mem-
branes are known to possess disproportionately high 
numbers of LDL receptors,
21 leading to active accu-
mulation of photosensitiser molecules at close 
proximity to tumour cells. Photosensitisers may also 
accumulate in tumours due to abnormalities in the 
local microvasculature, including disordered a blood 
supply and enhanced vascular permeability.
20,22
5-Aminolevulinic acid (ALA)
ALA is a small, water-soluble, prodrug that is a 
naturally occurring precursor in the biosynthetic 
pathway of haem. Administration of excess exog-
enous ALA avoids the negative feedback control 
that haem exerts over its biosynthetic pathway. Due 
to the limited capacity of ferrochelatase to convert 
PpIX into haem, the presence of excess exogenous 
ALA in cells induces accumulation of PpIX.
23–25 
This effect is pronounced in sebaceous glands and 
also in neoplastic cells. It has been reported that 
certain types of neoplastic cells have not only 
reduced ferrochelatase activity, but also enhanced 
porphobilinogen deaminase (PBGD) activity.
3,9,26 
Low ferrochelatase activity may be of lesser impor-
tant to deﬁ  ciencies in mitochondrial energy gen-
eration because tumour cells typically have low 
activities of mitochondrial cytochrome oxidase and 
utilise glycolysis rather than oxidative phosphor-
ylation.
17 In addition, certain malignant cells have 
low iron stores, a characteristic of proliferating 
cells, leading both to increased expression of trans-
ferrin receptors and, importantly, to decreased 
conversion of PpIX into haem.
27,28 Porphobilino-
gen deaminase is considered to have the lowest 
activity in the haem biosynthetic pathway
29,30 and 
the reason for its up-regulation in certain tumour 
cells has not yet been elucidated.
9 It is generally 
considered to be rate-limiting in the ALA-induced 
synthesis of PpIX in neoplastic cells.
31 Notwith-
standing this, other reports have failed to ﬁ  nd a 
clear relationship connection between high PBGD 
and/or low ferrochelatase activity and PpIX accu-
mulation.
32–34
Clinical administration of ALA
To date, clinical applications of PDT have been 
limited to areas of the body easily amenable to 
irradiation from laser or incoherent light sources. 
Consequently, PDT has been primarily investigated 
as a treatment for tumours and neoplasias of the 
skin, bladder, mouth and female reproductive tract. 
Compounds of high molecular weight (500 dal-
tons) have inherently low permeabilities of the 
stratum corneum barrier of the skin.
35 Therefore, 
notwithstanding a few isolated studies,
36,37 
pre-formed photosensitisers, which are generally 
large, highly conjugated molecules, are not com-
monly used in topical PDT. This, coupled with their 
inherent lack of selectivity, means that ALA, a 
photosensitiser prodrug with a relatively low 
molecular weight of 167.8 daltons, is the most fre-
quently employed agent in modern topical PDT.
PDT, based on topical application of ALA, has 
been successfully used in the treatment of basal 
cell carcinoma,
23,38,39 actinic keratosis,
24,40,41 
Bowen’s disease,
42–44 vulval intraepithelial neo-
plasia,
45–47 vulval Paget’s disease
48 and cervical 
intraepithelial neoplasia.
49 Due to the highly selec-
tive accumulation of PpIX in neoplastic cells 
resulting from topical application of ALA, the 
technique has also found use in the photodiagnosis 
(PDD) of neoplastic lesions of the mouth,
50 blad-
der,
51,52 endometrium
53 and cervix.
54 Illumination 
of the treated area with UV light causes reddish-
pink PpIX ﬂ  uorescence in neoplastic tissue, while 
the surrounding healthy tissue appears blue. The 
technique often allows detection of sub-clinical 
lesions, which may be missed by conventional 
means of examination.
PDT using topically applied ALA, in addition 
to producing successful therapeutic outcomes with 52
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excellent tissue preservation and no scarring, does 
not give rise to prolonged cutaneous phototoxic-
ity.38,55 Thus, ALA-PDT can be repeated often 
without causing accumulation of PpIX in normal 
skin.
11 This is particularly important when the aim 
of treatment is primarily palliative. This is in 
contrast to conventional PDT using the older 
preformed sensitisers, such as haematoporphyrin 
derivative. Repeated administration of such agents 
leads to persistent high photosensitiser levels in 
normal skin and severe phototoxic reactions after 
sun exposure.
10,23
As ALA is a small molecule, its diffusion into 
cutaneous tissue from a topical delivery system 
should be efﬁ  cient. However, the hydrophilic nature 
of ALA, as evident from its low octanol:water 
partition coefﬁ  cient of 0.03,
56 does impair permea-
tion markedly, since skin presents an essentially 
hydrophobic barrier to the permeation of exoge-
nously applied agents, As a result, topically applied 
ALA penetrates intact stratum corneum poorly, 
making it the principal barrier to effective absorp-
tion.
57,58 Fortuitously, the disordered stratum cor-
neum and disrupted epithelial barriers offered by 
many neoplastic lesions allow enhanced ALA pen-
etration, due to poor continuity in intercellular lipid 
structures.
8 This further improves the selectivity of 
PpIX accumulation and explains why ALA can be 
successfully employed for diagnostic purposes. 
However, its low lipophilicity
59 does prevent effec-
tive penetration into hyperkeratotic lesions,
38,40,60 
and may even facilitate efﬂ  ux, via the local micro-
circulation, from deep nodular lesions.
31
The clinical success of PDT relies on achieving 
a threshold concentration of ALA after topical 
application that induces therapeutic levels of 
protoporphyrin IX (PpIX) in abnormal cells. 
Failure to achieve this threshold leads to insuf-
ﬁ  cient amounts of PpIX and irradiation of the 
target cells will then not generate enough singlet 
oxygen to eradicate the lesion successfully. 
Clearly, it is important that this threshold is 
evaluated. Cell culture experiments have demon-
strated that concentrations of interstitial ALA 
must reach levels between 0.01 mg ml
−1 and 0.17 
mg ml
−1 before sufﬁ  cient PpIX is produced to 
cause a signiﬁ  cant (90% kill) level of neoplas-
tic cell death upon illumination with an optimised 
dose of red light.
15,61–63
The more common means of drug administra-
tion have been used for ALA delivery, such as the 
oral
64,65 and parenteral
64 routes. Although PpIX 
accumulation and prolonged patient photosensiti-
sation are not problematic, ALA has been shown 
to be rapidly eliminated from the human body, with 
a plasma half-life of 50 minutes when given intra-
venously and 4.5 minutes when given orally.
66 The 
small volume of distribution of only 8.3 L indicates 
that a large portion will be by broken down by 
ﬁ  rst-pass metabolism or excreted unchanged in the 
urine. Studies involving dogs revealed that 50% 
of an administered drug dose will distribute into 
the liver and that approximately 15% will distrib-
ute into the kidneys.67 The pharmacokinetic proﬁ  le 
of ALA is, therefore, highly unfavorable with 
respect to the generation of photodynamically 
efﬁ  cient levels of PpIX after systemic administra-
tion. Apart from its limited bioavailability, sys-
temic administration of ALA is associated with a 
number of side effects in humans. In addition to 
nausea, vomiting and transient abnormal liver 
functions, signiﬁ  cant decreases in systolic and 
diastolic blood and pulmonary pressure have been 
reported
68,69 side effects, such as nausea
70 and 
abnormalities of liver function, are of concern.
71,72 
This means that systemic ALA doses are limited 
to an upper ceiling of 60 mg kg
−1 in most cases. In 
addition, it has been reported that ALA, when given 
systemically, can permeate across the blood-brain 
barrier, but the clinical implications of this obser-
vation are still unclear.
73 These factors ensure that 
the topical route remains a viable alternative, espe-
cially when the neoplastic lesion is superﬁ  cial in 
nature. In such cases, the diffusion of ALA through 
the stratum corneum and its ability to reach deep 
sites becomes an important consideration. In a 
small number of studies, this barrier to ALA dif-
fusion has been bypassed completely and the drug 
has been administered via painful intracutaneous 
injection directly into skin tumours.
74,75 Generally, 
though, more conventional strategies to enhance 
ALA penetration into such lesions have been 
devised. These include physical methods, such as 
tape-stripping, curettage and iontophoresis and 
chemical methods, such as the use of penetration 
enhancers or, most commonly, chemical deriva-
tives of ALA.
8
Recently, numerous ALA derivatives have been 
synthesised by various groups Worldwide. The aim 
of this work has been improved bioavailability of 
both systemically- and topically-administered 
ALA. With respect to topically-applied ALA, 
lipophilic ALA derivatives have been produced in 
the hope of enhancing tissue penetration.53
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Synthesis of ALA and its Derivatives
ALA is a straight chained δ-amino acid (Fig. 2). In 
living organisms there are two possible routes that 
have been reported for ALA synthesis.
76 In the 
mitochondria of animals, yeast and fungi, ALA 
results from condensation of succinyl CoA and 
glycine, catalysed by ALA synthetase.
77 Plants, 
algae and nearly all bacterial groups utilise the 
5-carbon route to biosynthesis, where glutamate is 
converted to ALA along a three enzyme pathway.
78 
ALA can also be chemically synthesised from 
N-substituted amino acids and through stepwise 
build up of the carbon chain. Alternatively, amina-
tion of levulinc acid can also be employed.
79
Numerous ALA derivatives of varying lipophilic-
ities have been synthesised by reaction at either 
the amino group or carboxylic acid group (Fig. 2). 
ALA-containing dendrimers (Fig. 2), which are 
structurally defined hyper-branched polymers, 
have also been produced.
The most commonly-employed method to 
increase the lipophilicity of ALA has been to 
esterify the parent compound by reaction with an 
alkyl alcohol. ALA esters have typically been 
synthesised under standard conditions for esteriﬁ  -
cation of acidic drug substances, employing the 
appropriate alcohol and thionylchloride or hydro-
chloric acid.
80 By doing so, a large number of 
linear, branched, cyclic and ethylene glycol deriv-
atives have been prepared. However, in some 
instances it may be of beneﬁ  t to use tert-butylcar-
bonyl (BOC) chemistry to prevent cross reactivity 
when using carbodiimide coupling to activate the 
carboxylic function. However, care should be taken 
about the acid used for deprotection of the BOC 
function, because the resulting salts (e.g. HCl or 
NH2
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Figure 2. Chemical structure of 5-aminolevulinic acid (A) and general structures of its ester (B) and amide (C) derivatives and aminometh-
ane tris-methyl ALA (D) which contains three ALA residues coupled via ester linkages to a central core. This type of dendron forms the 
building block for the 2nd generation 6-ALA and 3rd generation 18-ALA dendrimers.
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TFA) might substantially alter the pharmacokinet-
ics of the active compound.
81 A number of halogen-
ated alcohol derivatives have also been synthesised 
that enhance lipophilicity further relative to their 
hydrocarbonyl counterparts. In this way, the 
lipophilicity of ALA can be modiﬁ  ed over several 
orders of magnitude.
82
The alternative approach to alter the lipophilicity 
of ALA using a simple derivatisation is to convert 
the aminogroup into an amide. In its most simple 
embodiment, this can be achieved by the conden-
sation of ALA or one of its ester derivatives with 
acetic anhydride or acetylchloride under basic 
conditions.
80
It is known that elevated levels of aminopepti-
dase activity exist in certain human tumour cell 
lines and in tumour-associated vasculature.
83–85 
The use of aminoacyl derivatives of ALA to 
address these altered enzymatic activities has been 
investigated experimentally by Berger et al.
86 who 
prepared a number of BOC-protected and depro-
tected pseudopeptide derivatives of ALA and ALA 
esters and dipeptide derivatives of ALA.
87 The aim 
was to utilise these compounds to further enhance 
the selectivity of PpIX accumulation in neoplastic 
cells rather than to enhance lipophilicity for 
enhanced percutaneous penetration.
One chemical strategy aimed at overcoming the 
poor systemic bioavailability of ALA has been the 
synthesis of structurally-deﬁ  ned ALA-containing 
dendrimers. In this way, a number of ALA mole-
cules can be delivered by the same dendrimer. The 
minimal structure of a dendrimers is known as a 
dendron. Such dendron and dendrimers moieties 
exhibit the enhanced permeability and retention 
effect in tumours.
88 This may enhance tumour-
speciﬁ  c ALA delivery and lead to increased spe-
ciﬁ  city of PpIX accumulation in tumour cells.
Tissue Penetration of Topically-
applied ALA and ALA-derivatives
Numerous literature reports describe both in vitro 
and in vivo penetration of topically applied ALA 
into tissue. However, while a range of techniques 
have been used to assess the ﬁ  nal penetration depth, 
few report on the speciﬁ  c ALA concentrations 
found at various depths from the plane of surface 
absorption. Most studies to date have used ﬂ  uores-
cence microscopy to investigate the formation of 
PpIX in tissue, after topical application of ALA. 
In the majority of cases, an ALA-containing vehi-
cle is applied topically to normal or diseased skin 
of animal or human volunteers. The formulation 
is generally left in place for 4–6 hours before a 
biopsy is taken from the application site. Section-
ing of the biopsy allows the ﬂ  uorescence intensity 
of PpIX to be evaluated using suitable microscopy 
with excitation wavelengths around 400 nm and 
emission wavelengths from 600–700 nm.
3,88 Alter-
natively, PpIX is extracted from dissolved tissue 
samples and determined using ﬂ  uorescence spec-
trophotometry with similar excitation and emission 
wavelengths as above.
27,89,90 It is clear that most 
studies tend to be qualitative in nature, comparing 
PpIX ﬂ  uorescence with background auto-ﬂ  uores-
cence. They serve, simply, to give an indication of 
depth of PpIX formation and, by inference, ALA 
penetration. Konig et al.
91 reported PpIX ﬂ  uores-
cence at a depth of 0.6 mm, 6 hours after topical 
ALA application, in patients with skin tumours. 
Szeimies et al.
92 reported PpIX ﬂ  uorescence at a 
depth of 0.3 mm in basal cell carcinomas (BCC). 
In contrast, Pahernik et al.
93 reported PpIX ﬂ  uo-
rescence at depths as low as 3 mm in hamster skin 
tumour models.
Wennberg et al.
94 used microdialysis to quantify 
ALA in normal skin and BCC after topical applica-
tion of ALA (20% w/w) in an aqueous gel. A 
microdialysis tube was inserted intracutaneously 
at a depth of 0.5 mm and samples were taken at 
regular time intervals for analysis by high perform-
ance liquid chromatography (HPLC). The concen-
tration of ALA in BCCs at a depth of 0.5 mm was 
found to range between 0 mg ml
−1 and 0.52 mg 
ml
–1. No ALA could be detected in normal skin at 
this depth. While this study was able to quantify 
ALA concentrations at a depth of 0.5 mm, the drug 
concentrations above and below this depth could 
not be assessed, nor could the depth of ALA pen-
etration.
Casas et al.
57 using liquid scintillation spectrom-
etry, showed that ALA could penetrate model 
mouse tumours down to depths of 5 mm, although 
the majority of drug was found in the upper 2 mm 
of tissue. ALA concentrations at the different 
depths were not reported, in contrast to the studies 
carried out by Ahmadi et al.
95 and McLoone et al.
96 
In these studies, the authors used liquid scintillation 
spectrometry to determine the concentrations of 
ALA at varying depths from the surface of nodular 
BCC. Concentrations of ALA as high as 20 mg 
ml
−1 were detected at depths as low as 2 mm in 
these nodular lesions. However, once the integrity 55
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of the SC is more intact, as in normal skin, then 
permeation is shown to slow. Johnson et al.
97 used 
autoradiography to demonstrate that the majority 
of a topically applied ALA dose did not penetrate 
porcine skin much deeper than the lower reaches 
of the stratum corneum. The same authors, using 
scintillation spectrometry, reported that ALA past-
ing through the entire stratum corneum barrier only 
achieved depths of 100–150 µm in underlying tis-
sue. The importance of the stratum corneum as a 
barrier to ALA penetration was illustrated by Don-
nelly et al.
98 The authors showed, using autoradi-
ography, that topically applied ALA could penetrate 
vaginal tissue, which possesses no stratum cor-
neum barrier, down to depths of at least 6 mm.
The lipophilicity and molecular weight of a drug 
substance are considered to be the primary deter-
minants of diffusivity through stratum corneum.
99 
This layer of the epidermis comprises mostly anu-
cleate cells and is associated with providing the 
principal barrier function in respect of transdermal 
delivery of drugs. The stratum corneum has been 
portrayed as the often cited ‘brick and mortar’ 
model in which keratinised cells are embedded in 
a mortar of lipid bilayers. The intercellular route 
of drug diffusion through the will not, therefore, 
be an accessible phase for either very polar or 
charged species.
Enhanced permeability through the lipid net-
works in the stratum corneum can be undertaken 
by chemical derivatisation of ALA.
100,101 This pro-
drug strategy imparts a greater lipophilicity to the 
parent ALA compound, usually accomplished by 
formation of a labile bond at the amino
86,87 or, most 
commonly, the carboxylic acid group of the parent 
ALA molecule. Table 1 shows the octanol/water 
partition coefﬁ  cients and the stratum corneum/
water partition coefﬁ  cients of ALA and several 
commonly employed ALA esters. It can be seen 
clearly that increasing the alkyl chain length of 
ALA esters signiﬁ  cantly enhances lipophilicity and 
the ability to partition into the stratum corneum. 
However, within a homologous series, drug perme-
ability usually increases with log Poct up to a 
maximum, at which point transport becomes lim-
ited due to sequestration of the drug within the 
lipophilic barrier. Consequently, following topical 
application to skin, PpIX ﬂ  uorescence induced by 
ALA esters is localised to the site of application, 
while fluorescence arising from ALA-induced 
PpIX is typically observed at distant locations. This 
effect may be directly attributable to pro-drug 
sequestration within the stratum corneum, whereas 
the more hydrophilic ALA is able to penetrate to 
vascular networks more effectively. However, 
since PpIX and ALA are completely cleared from 
the body within 24 hours of administration,
102 
prolonged and undesirable widespread cutaneous 
photosensitivity is not problematic.
Numerous in vitro and in vivo studies have been 
carried out to assess the ability of ALA esters to 
enhance penetration and PpIX production. The 
majority of in vitro investigations reveal that 
increased amounts of ALA esters, relative to the 
parent compound, only penetrate stratum corneum 
after prolonged application times, sometimes 
approaching 30 hours. Working within a frame-
work of clinically relevant application times, such 
as 4 or 6 hours, no signiﬁ  cant difference is observed 
in amounts of ALA or ALA-esters penetrating 
stratum corneum, regardless of ester alkyl chain 
length.
103–105 The in vivo studies have typically 
investigated PpIX production in the skin of human 
volunteers106–108 or nude mice
88,101,109,110 following 
topical application of ALA or one of its esters. 
Again, signiﬁ  cant lag times are generally observed 
before PpIX ﬂ  uorescence induced by ALA esters 
becomes greater than that induced by ALA. These 
observations are in contrast to those found in PDD 
of dysplasia and early bladder cancer, which 
showed that the ALA hexyl ester could not only 
reduce instillation times, but induce a 2-fold 
Table 1. Log Poct and log PSC/W for ALA and its ester derivatives.
Compound
‡  Mol. Wt. (Da)  log Poct
* log  PSC/W
†
ALA 167.6  −1.5  −1.4
Methyl-ALA 181.6 −0.9 0.2
Butyl-ALA 223.8 1.4  0.3
Hexyl-ALA 251.8  1.8  0.9
Octyl-ALA 279.6 2.6  1.0
*P oct is the partition coefﬁ  cient between octanol and aqueous buffer solution (pH 7.4, 21 °C), as calculated by Uehlinger et al. (2000).
82
†PSC/W is the partition coefﬁ  cient between stratum corneum and water, as calculated by De Rosa et al. (2003).
104
‡hydrochloride salt (HCl.H2N-CH2-CO-CH2-COOR
1 = general structure).56
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increase in ﬂ  uorescence signals with a 20 times 
lower concentration of ALA hexyl ester compared 
to ALA.
52 These ﬁ  ndings were attributed to the 
different properties of the urothelial and stratum 
corneum permeability barriers.
To date, no studies have been carried out on 
tissue penetration of amide derivatives of ALA or, 
understandably, ALA dendrimers.
Cellular Uptake and Metabolic 
Conversion of ALA and ALA-
derivatives
The tetrapyrrolic structure of porphyrins means 
that ALA amides must be cleaved before entering 
the haem biosynthetic pathway. This hypothesis is 
supported by the experimental observation that 
ALA amides and their esters generally fail to 
induce large amounts of PpIX in vitro80,86,111 and 
in vivo80,111 in the absence of speciﬁ  c peptidases. 
Moreover, Moan et al.
112 have shown that an 
N-formyl ALA derivative neither induced porphy-
rin synthesis nor inhibited the formation of PpIX 
induced by ALA. However, as discussed previ-
ously, these characteristics might be advanta-
geously used to further increase the selectivity of 
ALA-induced PpIX accumulation by targeting 
speciﬁ  c proteases found in abundance in some 
tumors.86,113,114
It is well accepted that ALA-containing den-
drimers and dendrons must release their cargo in 
order to allow PpIX production. However, this does 
not necessarily have to occur outside the cell, with 
intact dendrons having been detected within cells 
in vitro.
115 Dendrimers containing up to 18 ALA 
residues have been prepared and used to substan-
tially improve PpIX production in cells relative to 
ALA.
116 Experiments performed with ALA-con-
taining dendrimers and dendrons have generally 
produced mixed results, however 115–117. Release 
from the ALA-containing structure may be prob-
lematic, as evidenced by the fact that two thirds of 
intracellular tetrameric ALA-containing dendrons 
remained intact 3 hours after administration.
115
Thus, ALA amides must be cleaved and ALA-
containing dendrimers must also be able to efﬁ  -
ciently release ALA in order to be potent substrates 
for PpIX production.
ALA-induced formation of PpIX depends on the 
penetration of ALA through the cell membrane. 
Being a zwitterion with pKa values of 4 (carboxy-
lic acid group) and 8.9 (amino group),
57 the 
lipophilicity of ALA is unlikely to change 
signiﬁ  cantly in the physiological pH range. It is 
expected, therefore, that ALA is unlikely to enter 
cells by passive diffusion alone. In Salmonella 
typhimurium
118 and Escherichia coli
119 the dipeptide 
permease is probably responsible for ALA transport 
across the cell membrane. In eukaryotic cells, the 
uptake mechanisms are not clear. ALA uptake may 
rely on an active transport mechanism, as exempli-
ﬁ  ed by that in Saccharomyces cerevisieae, which 
shows an apparent Km of 0.1 mM at an optimum 
extracellular pH of 5.0.
120 Mammalian cells may 
possess additional cell-type dependent mecha-
nisms,
9 since ALA uptake in rat cerebellum parti-
cles, for example, was found to be nonsaturable up 
to 4 mM of ALA.
62 In addition, Rud et al.121 showed 
that ALA is transported into human adenocarci-
noma cells by β–amino acid and γ–aminobutyric 
acid carriers and is Na
+ and partly Cl
– dependent. 
The PEPT1 and PEPT2 transporters have also been 
identiﬁ  ed as potential transporter systems for ALA 
uptake.122,123
The methyl ester of ALA has been shown to be 
taken up actively by WiDr cells using transporters 
of non-polar amino acids.
124 However, longer chain 
aliphatic ALA esters are not transported by these 
carriers and it has been postulated that they may 
enter cells by either passive diffusion or endocy-
tosis.
125,126 Once in the cell, the esters may be 
converted to ALA by non-speciﬁ  c esterases. Alter-
natively, the esters may be hydrolysed to ALA 
outside the cell. Indeed the skin, in particular, pos-
sesses a multitude of different enzymes by which 
topically applied drugs can be metabolized.
127 
However, it has yet to be demonstrated conclu-
sively that short chain ALA esters actually need to 
be hydrolysed in order to enter the haem biosyn-
thetic pathway.
128 While it is accepted that steari-
cally-hindered, or extremely large ALA esters 
would be unable to act as substrates for porpho-
bilinogen synthetase, which converts two ALA 
molecules into porphobilinogen (Janet et al. 2000), 
short chain esters may be able to produce PpIX 
esters, which are likely to have very similar pho-
tochemical properties to PpIX.
Cell culture studies have demonstrated that 
aliphatic straight chain ALA esters, up as far as the 
hexyl ester in the homologous series, induce higher 
levels of PpIX in neoplastic cells more rapidly 
than the parent compound,
62,63,80,82,109,129,130 
presumably due to their non-requirement for a 
saturable active transport mechanism. The optimum 57
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PpIX fluorescence in intact murine mammary 
cancer cell spheroids (275–350 µm) was shown 
using 0.05 mM hexyl ALA, almost 200 times lower 
than the optimum concentration of ALA (10 mM). 
This indicated that not only did the interior cells 
maintain esterase activity and porphyrin synthesis, 
but that hexyl ALA diffused efﬁ  ciently to the 
spheroid interior.
131
It has been suggested that lower concentrations 
of ALA esters, with shorter application times would 
increase the efﬁ  cacy of PDT and PDD.
125 However, 
with the exception of the case of bladder instilla-
tion, topical application of ALA esters does not 
seem to provide such an advantage. The results 
obtained from in vitro cell culture studies demon-
strate that the time required for cleavage of the 
ester group to yield free ALA appears to be insig-
niﬁ  cant and does not seem to limit the usefulness 
of ALA esters. Retention in, and gradual release 
from, the stratum corneum, as discussed above, in 
combination with poor release from the topically 
applied vehicle may, therefore, be mostly respon-
sible for the observed lag times before signiﬁ  cant 
in vivo PpIX production. In spite of this, ALA 
methyl ester has been shown to be effective for 
PDT of nodular basal cell carcinoma
59,132,133 
where ALA PDT has historically produced poor 
results.
134,135 However, it should be pointed out 
that these clinical studies used curettage/debulking 
to remove the stratum corneum and some of the 
carcinoma before treatment, and also routinely 
used a 1–2 treatment cycles that each involved two 
treatments a week apart. Nevertheless, a topical 
cream containing 16% w/w methyl ALA (Metvix
®, 
Photocure, Norway) has received market authori-
sation in the US and Europe.
Stability of ALA and its Derivatives
ALA belongs to the class of α-aminoketones, 
which dimerise readily under alkaline condi-
tions.
136 The formed dihydropyrazines can further 
oxidise to pyrazines. Formulation of ALA into drug 
delivery systems for photodynamic therapy has 
necessitated the derivation of its degradation path-
ways. Under alkaline conditions, the formation of 
3,6-dihydropyrazine 2,5-dipropionic acid (DHPY), 
porphobilinogen and pseudo-porphobilinogen, via 
an open-chain dimeric ketimine, from ALA has 
been postulated previously. Furthermore, the oxi-
dation of DHPY to pyrazine 2,5-dipropionic acid 
(PY) has also been reported. The possible 
condensation products of ALA, formed under 
alkaline conditions and in the absence of enzymes, 
according to the literature, are shown in Figure. 
3(A)
137–141 Dalton et al. 1999. In addition to the 
cyclic degradation products, it has also been sug-
gested that ALA may undergo a polymerisation 
reaction in solution.
142
Initially, the published reports on ALA degrada-
tion mechanisms and products were conﬂ  icting. 
This conﬂ  ict can be ascribed to the variety of sta-
bility test conditions and analytical methods used. 
Most studies did not elucidate the structure of the 
degradation products. However, Bunke et al.
143 
using capillary electrophoresis (CE) and nuclear 
magnetic resonance spectroscopy (NMR), have 
shown that only two condensation products for 
ALA exist in alkaline media in the absence of 
enzymes. DHPY is formed initially and this is then 
oxidised to PY, which is the major degradation 
product in aerated solutions. Neither porphobilino-
gen nor pseudo-porphobilinogen are formed under 
such conditions. Novo et al.
51 De Blois et al.
144 and 
Gadmar et al.
142 using ultraviolet spectroscopic 
methods, have come to similar conclusions.
The stability of 5-aminolevulinic acid (ALA) 
in aqueous solution has been shown to be depend-
ent on four factors, namely, pH, concentration, 
temperature and degree of oxygenation of the solu-
tion.
51,142,144,145
It has been proposed that 2 molecules of ALA 
can only react to form 3,6-dihydropyrazine 2,5-
dipropionic acid (DHPY), when the amino group 
of the ALA is deprotonated. The DHPY is then 
oxidised to pyrazine 2,5-dipropionic acid in aerated 
media.
51 The pH dependence of the reaction of 
ALA can, thus, be explained on the basis of the 
acid-base equilibria of this amino acid,
146 which is 
shown diagrammatically in Figure. 3(B).
The values of the acid dissociation constants 
(pKa) of ALA have been shown to be around pK1 = 
4.0 and pK2 = 8.3.
51,147 These values indicate that 
the zwitterion is the major species present in the 
pH range between 5 and 7.5, although signiﬁ  cant 
amounts of the two other acid-base species exist, 
depending on the acidity. Therefore, at pH 5.0, 
about 10% of the ALA molecules are cations, 
whereas around pH 7.3, for example, about 10% 
of the ALA molecules are anions. Accordingly, a 
scheme similar to that proposed by Butler and 
George
140 could explain the reaction involving 
ALA. The anion, a species with a deprotonated 
amino group, is the only one able to react with the 58
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ketone group of a neighbouring molecule to yield 
the cyclic dihydropyrazine, DHPY. For the con-
densation to occur, the amino group of ALA should 
be deprotonated. This explains the strong pH 
dependence of the reaction, since the concentration 
of the anion increases with the pH. Therefore, ALA 
solutions are only stable at low pH values, where 
the anion does not exist.
The theories discussed above have been inves-
tigated experimentally by a number of workers. 
De Blois et al.
144 showed that ALA solutions, of 
an initial concentration of 0.1% w/w and pH values 
Figure 3. Possible condensation reactions involving 5-aminolevulinic acid (A) and pH-dependent equilibria occurring in aqueous solutions 
of 5-aminolevulinic acid (B) Adapted from Novo et al. (1996).
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of pH 4.0, were still within the pharmaceutically 
acceptable range of 90–100% w/w ALA after 128 
days storage at 21 °C. At pH 8.0 the ALA content 
declined below the 90% w/w limit within a few 
days. Elfsson et al.
147 found that solutions of ALA, 
buffered to pH 2.35 were completely stable over a 
period of 37 days, even when stored at 50 °C. The 
half lives for the decomposition of ALA at pH 4.81 
and pH 7, respectively, at 50 °C were 257 hours 
and 3 hours, respectively. Novo et al.
51 showed that 
a 0.3 M solution of ALA in distilled water had a 
pH of 2 and was completely stable under various 
conditions of storage. All three groups reported 
decrease in pH in degrading solutions of ALA. This 
may be explained by the fact that as the anion 
reacts, the concentration of protons increases in 
the solutions of ALA in order to maintain the zwit-
terion-anion equilibrium.
51,144
The degradation of ALA has been shown 
experimentally to follow second order kinet-
ics.
144,145 Hence, doubling the concentration of 
ALA in a solution of a given temperature and pH 
should quadruple its rate of decomposition. De 
Blois et al.
144 showed that a solution at pH 5.0, 
with an initial ALA concentration of 0.5% w/w, 
had ALA concentrations that were still higher than 
90% w/w after 178 days storage. Solutions with 
initial ALA concentrations of 2, 5 and 10% w/w, 
had ALA contents which dropped below the 90% 
limit after 150, 94 and 29 days, respectively. 
Elfsson et al.
147 used Arrhenius plots to interpret 
the results from accelerated storage testing of ALA 
solutions. The authors showed that a 1% w/w 
solution of ALA, stored at pH 7.53, would have a 
shelf life, or t90, the time it takes for a substance 
to lose 10% of its initial mass, of 1.9 hours at 
20 °C. The shelf life (t90) of a 10% w/w solution 
of ALA at pH 7.53 would be as short as 10 minutes 
at 20 °C.
It is well known that, in general, as the concen-
tration of a reactant is increased, the rate of reaction 
increases. Elfsson et al.
147 incubated 1% w/w solu-
tions of ALA at pH 7.53 and at temperatures rang-
ing from 37 °C to 85 °C. It was shown that, for 
every 10 °C rise in temperature, the rate of ALA 
degradation increased by a factor of around 1.5.
The initial second order degradation of ALA to 
give DHPY has been shown to be reversible by 
acidiﬁ  cation of the solution, providing no oxygen 
is present in the reaction mixture
145 If oxygen is 
present then the DHPY is irreversibly converted 
to PY and the ALA lost is irretrievable.
During degradation, aqueous solutions of ALA 
are reported to undergo colour changes over time, 
changing from colourless to yellow and then to 
red/orange.
144,145 The yellow colouration is attrib-
uted to DHPY, based on UV studies of deaereated 
solutions,
51 while the red colour is attributed 
to PY.
145
The above considerations have led to the devel-
opment of various strategies for maintaining the 
stability of ALA in solution. Neither addition of 
ethylene diamine tetra acetic acid (EDTA)
142,147 
nor antioxidants
145 to ALA solutions was able to 
prevent degradation. Most workers have advised 
dissolving ALA in solutions buffered to around pH 
2.0 to maintain long-term stability. Due to the 
potential for cutaneous irritancy at such pH values, 
ALA solutions, buffered to physiological pH val-
ues, such as pH 5.5 or pH 7.4, are normally pre-
pared immediately prior to use.
The majority of studies on ALA stability have 
investigated degradation in simple aqueous solu-
tion or in drug delivery systems. However, a 
number of studies have shown that PY can also be 
formed readily under in vivo conditions.
141,148 
Given that this compound has unknown toxicity, 
its formation in drug delivery systems and in vivo 
should be kept to a minimum.
Little published data exists on stability of ALA 
derivatives. Data on hydrolysis of ALA esters 
under various in vitro conditions even appears to 
be scarce, though the hexyl ester seems quite resist-
ant to hydrolysis.
149 All ALA esters have the poten-
tial to be hydrolysed in vivo by, for example non 
speciﬁ  c esterases in the skin or blood. Indeed, the 
esters may form pyrazine-type degradation prod-
ucts in vitro and in vivo before or after hydrolysis. 
However, we have previously shown
150 that 
increasing the ester chain length can substantially 
reduce formation of pyrazine-type degradation 
products. ALA amides are likely to possess good 
stability proﬁ  les, as dimerisation will be prevented 
by stearic hindrance at the amino group. Similarly, 
ALA locked into dendron or dendrimers structures 
will be unable to react to produce degradation 
products, as they are not free to move.
Drug Delivery Considerations
ALA and its derivatives are, in most cases, 
intended for topical application. However, as we 
have highlighted previously,
8,151 despite the vast 
number of studies published in this area, a rational 60
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approach to formulation design has not taken 
place. When formulating a topical drug delivery 
system the aims should be to maximise the ther-
modynamic activity of the drug substance in the 
vehicle, so as to maximise the concentration drive 
for diffusion and maximise the partition coefﬁ  cient 
between stratum corneum and vehicle. For exam-
ple, formulating a relatively lipophilic ALA 
derivative, such as the hexyl ester in an aqueous 
vehicle should maximise its ﬂ  ux into skin when 
applied topically.
Studies published to date on topical application 
of ALA and its derivatives have used aqueous solu-
tions, oil in water creams, water in oil creams, 
hydrogels, organogels, aqueous and solvent-based 
patches and particulate delivery systems. These 
dosage forms, which in many cases seem to have 
been selected at random with little regard to their 
nature, possess a multitude of different physico-
chemical properties. This has made comparison of 
different studies difﬁ  cult. As a result, the true value 
of derivatisation of ALA to yield more lipophilic 
prodrugs has been blurred somewhat. One example 
of such problematic comparisons lies in the ionto-
phoretic delivery of ALA esters. ALA esters have a 
net positive charge at physiological pH. Because 
of this, electrorepulsion can be used to enhance the 
delivery of methyl ALA over and above that of 
ALA by approximately 50 times.
107,152 The mag-
nitude of this effect gradually decreased with 
increasing chain length within a homologous series 
of ALA esters. Conversely, Gerscher et al.
106 could 
detect no signiﬁ  cant difference between the levels 
of PpIX induced in vivo after iontophoresis of 
solutions of ALA, butyl ALA or hexyl ALA. This 
may have resulted from the acidic solutions used 
in vivo, which converted a greater fraction of ALA 
to the cationic form and elevated hydronium con-
centration. The latter carries charge more efﬁ  -
ciently than ALA esters, and reversed the direction 
of electroosmotic ﬂ  ow.
125
In order to uncover the true potential of ALA 
derivatives, a systematic formulation/skin pene-
tration study is required. ALA derivatives (ester 
or amide) of increasing lipophilicites should be 
incorporated at deﬁ  ned concentrations into drug 
delivery vehicles, themselves of variable lipophilic 
character. The penetration characteristics of these 
drug/vehicle combinations should then be studied 
using excised skin, with the drugs quantiﬁ  ed by 
HPLC or other sensitive analytical method.
Conclusion
Chemical derivatives of 5-aminolevulinic (ALA) 
have the potential to improve bioavailability, 
enhance stability and lead to better therapeutic 
outcomes for treated patients. However, despite 
extensive recent investigation, ALA derivatives 
have yet to demonstrate meaningful clinical 
beneﬁ  ts, with the use of hexyl ALA for photodi-
agnosis of bladder neoplasias a notable exception. 
A rational approach to topical formulation design 
is required, along with a systematic study aimed 
at uncovering the true potential of ALA derivatives 
in photodynamic therapy. With respect to systemic 
ALA delivery, more study is required in the area 
of ALA-containing dendrons and dendrimers, with 
the aim being to enhance the selectivity and efﬁ  -
ciency of ALA delivery and PpIX production while 
reducing systemic side effects.
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